the use of the ki-67 in deciding which patients with hr breast cancer can safely avoid chemotherapy
Published 2 years ago • 5.1K plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
6:09
ki-67 index after neoadjuvant et as a prognostic biomarker for hr /her2- early breast cancer
-
2:24
evaluating the requirement for chemotherapy in patients with hr bc
-
1:17
perelisa: de-escalated therapy for hr /her2 bc with ki67 response following 2-week letrozole
-
2:25
comment: lumina results show that women with low levels of the ki67 biomarker can avoid outcomes...
-
1:52
dr. ellis discusses ki67 as a treatment monitoring biomarker
-
1:01
dr. nielsen on the challenges of using ki67 as a tool in breast cancer
-
0:49
dr. nielsen on the clinical utility of ki67 in breast cancer
-
2:12
the impact of adjuvant chemo on os in hr and node bc with an oncotype dx score of 25 or less
-
1:47
can we decrease chemotherapy in ln premenopausal women based on genomic tests?
-
1:12
the use of ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients
-
1:19
dr. nielsen on the pros and cons of the ki67 assay in breast cancer
-
1:38
role of ki 67 index in grading of mtc
-
2:07
lumina results: women with low levels of the ki67 biomarker can avoid outcomes related to rt
-
5:34
neos: prognosis of er breast cancer pts who received neoadjuvant et with/without adjuvant chemo
-
1:09
priya rastogi, md, provides details on the subgroup of patients with ki-67 status from monarche
-
10:05
ki-67 shows proven clinical utility as a predictive clincal biomarkers for breast cancer
-
1:29
dr. nielsen discusses using a ki67 assay in breast cancer
-
3:08
the molecular differences between younger versus older er-positive and her2-negative breast cancers
-
0:50
dr. ellis discusses the cell-proliferation marker ki67